Roche, Isis ally to develop Huntington's disease drugs

04/9/2013 | Yahoo

Roche Holding and Isis Pharmaceuticals agreed to collaborate in the development of Huntington's disease drugs using the latter's antisense technology. The partners will initially focus on Isis' lead drug candidate designed to inhibit production of all forms of a protein involved in the genetic brain disorder. Isis will get $30 million upfront and as much as $362 million in licensing and milestone fees plus sales royalties on drugs arising from the collaboration.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR